asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

MobiKwik partners with Cashfree Payments to offer its ZIP payment option to over 20,000 online retailers

by asianprimenews0879

Gurugram, 31 August 2023: MobiKwik, a leading digital banking platform, today announced its partnership with Cashfree Payments, a leading payments and API banking company, to offer the convenience of interest-free credit for its users at their fingertips by integrating ‘ZIP Pay Later’ with Cashfree Payments’ Payment Gateway. It will enable users to use their ZIP credit limit of up to Rs 60,000 to pay at over 20,000 online merchants. The ZIP Pay Later option will be launched with 10% Supercash on a minimum transaction value of Rs 499.
Upasana Taku, Chairperson, Co-founder & COO of MobiKwik, said, “We believe in making transactions seamless and empowering consumers by offering them more choices to make informed financial decisions. We are glad to extend our partnership with Cashfree Payments, bringing together the convenience of our popular ZIP Pay Later option with a trusted and efficient payment gateway platform like Cashfree Payments to make the process more seamless.”
MobiKwik ZIP ensures a seamless payment experience with an impressive success rate of over 95%. The ZIP pay later option allows users to pay bills, shop for clothes, groceries, and electronics, order food, medicines, and much more with their credit limit. With ZIP, users can shop at over one lakh brands simply from the comfort of their homes using MobiKwik at the checkout and just pay later.
Reeju Datta, Co-Founder, Cashfree Payments said, “At Cashfree Payments, we are committed to empowering our merchants with seamless payment experiences that are both scalable and affordable. With this partnership, we aim to take this mission to the next level. Our goal is to enable customers to pay for their purchases in the most flexible and convenient manner possible, without any unnecessary hassles. We hope to drive greater financial inclusion across India and deliver even more value to end customers by working closely with MobiKwik.”
Merchants can also seamlessly integrate MobiKwik ZIP into their existing Cashfree Payments checkout, offering their customers a cutting-edge payment solution. With a success rate of over 95%, merchants can be assured of providing a smooth payment experience to their users. By offering credit options, merchants can also witness an upsurge in conversions, as customers embrace the flexibility of deferring payments.
MobiKwik ZIP is applicable on top brands across the country. The partnership between MobiKwik and Cashfree Payments is set to bring significant benefits to customers, merchants, and both companies involved.

About MobiKwik
MobiKwik is a digital banking platform that offers a comprehensive suite of financial products for both consumers and merchants. Our products range from payments to digital credit and investments, enabling our users to meet their financial needs seamlessly. Our mission is to empower millions of people with access to affordable and convenient financial services, regardless of location or income level.

Founded in 2009 by Bipin Preet Singh and Upasana Taku, MobiKwik has grown to serve over 140 million registered users across India. With a merchant network of over 4 million, MobiKwik is one of the most trusted and widely used digital banking platforms in India.

We are currently in a new phase of innovation at MobiKwik, as we work towards our goal of building a world-class digital banking platform for Bharat.

About Cashfree:
Cashfree Payments is a leading payment and API banking solutions company. It provides full-stack payments solutions enabling businesses in India to collect payments and make payouts via all available methods with simple integration. Cashfree Payments’ offerings include an advanced and easy way to integrate payment gateways, a split payment solution for marketplaces, bank account verification API, and Auto Collect — a virtual account solution to match inbound payments to customers. Founded by IIIT Hyderabad alumnus Akash Sinha and IIT Kharagpur graduate Reeju Datta, www.cashfree.com is among the leading payment service providers in India processing transactions worth USD 40 Billion annually. It has leveraged technology to lead payment disbursals in India with more than 50% market share among payment processors. Cashfree Payments enables more than 1,50,000 businesses with payment collections, vendor payouts, wage payouts, bulk refunds, expense reimbursements, loyalty and rewards. Apart from India, Cashfree Payments products are used in eight other countries including the USA, Canada, and UAE. Cashfree Payments is backed by Silicon Valley investor Y Combinator, Apis Partners, State Bank of India (SBI), and was incubated by PayPal.

For further information, please contact:
Mrinall Kanti Dey, VP & Head – Corporate Communications
Mrinall.dey@mobikwik.com | +91-9818449509
Sinoj Sadanandan | +91-9619375635
sinoj.sadanandan@cashfree.com
Mebin Mathew, Senior Manager – Current Global
Mmathew@currentglobal.com | +91-9899548502

Share

Related posts

YRF & Mohit Suri’s Saiyaara records Highest Monday for an Indian Film in 2025, Ahaan-Aneet 1st debutants to enter 100 crore club in just 4 days!

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

Housing.com Launches AI-Powered Price Trend Engine to Enhance Home Search Experience

asianprimenews